Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisen, T, Boshoff, C, Mak, I, Sapunar, F, Vaughan, M M, Pyle, L, Johnston, S R D, Ahern, R, Smith, I E, Gore, M E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374399/
https://www.ncbi.nlm.nih.gov/pubmed/10732751
http://dx.doi.org/10.1054/bjoc.1999.1004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374399/
https://www.ncbi.nlm.nih.gov/pubmed/10732751
http://dx.doi.org/10.1054/bjoc.1999.1004

Ejemplares similares